<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093116</url>
  </required_header>
  <id_info>
    <org_study_id>TPX-0005-01</org_study_id>
    <nct_id>NCT03093116</nct_id>
  </id_info>
  <brief_title>A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements</brief_title>
  <acronym>TRIDENT-1</acronym>
  <official_title>A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turning Point Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turning Point Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the&#xD;
      maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose&#xD;
      (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an&#xD;
      ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.&#xD;
&#xD;
      Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction.&#xD;
&#xD;
      Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded&#xD;
      Independent Central Review (BICR) of repotrectinib in each subject population expansion&#xD;
      cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene&#xD;
      rearrangement. The secondary objective will include the duration of response (DOR), time to&#xD;
      response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit&#xD;
      rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a&#xD;
      ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Phase 2, study subjects will be enrolled into 6 distinct expansion (EXP) cohorts:&#xD;
&#xD;
        -  EXP-1: ROS1 TKI-naïve ROS1+ NSCLC. Up to one prior line of chemotherapy OR immunotherapy&#xD;
           is allowed&#xD;
&#xD;
        -  EXP-2: 1 Prior ROS1 TKI AND 1 Platinum-based Chemotherapy ROS1+ NSCLC. Disease&#xD;
           progression, or intolerant to one prior line of a ROS1 TKI. Must have received one prior&#xD;
           line of platinum based chemotherapy OR one prior line of platinum based chemotherapy in&#xD;
           combination with immunotherapy before or after a ROS1 TKI&#xD;
&#xD;
        -  EXP-3: 2 Prior ROS1 TKIs AND NO Chemotherapy ROS1+ NSCLC. Disease progression, or&#xD;
           intolerant to 2 prior lines of a ROS1 TKI treatment. No prior lines of chemotherapy or&#xD;
           immunotherapy are allowed.&#xD;
&#xD;
        -  EXP-4: 1 Prior ROS1 TKI and NO Chemotherapy or Immunotherapy. Disease progression or&#xD;
           intolerant to one prior line of a ROS1 TKI. No prior lines of chemotherapy or&#xD;
           immunotherapy are allowed.&#xD;
&#xD;
        -  EXP-5: TRK TKI-naïve NTRK+ solid tumors. Any number of prior lines of chemo or&#xD;
           immunotherapy is allowed.&#xD;
&#xD;
        -  EXP-6: TRK TKI-pretreated NTRK+ solid tumors. Disease progression, or intolerant to 1 or&#xD;
           2 prior TRK TKIs. Any number of prior lines of chemo- or immunotherapy are allowed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLTs) (Phase 1)</measure>
    <time_frame>Within 28 days of the first repotrectinib dose</time_frame>
    <description>Define the dose limiting toxicities (DLTs) (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) (Phase 1)</measure>
    <time_frame>Within 28 days of the last patient dosed in escalation</time_frame>
    <description>To determine the RP2D (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) Phase 2</measure>
    <time_frame>Two to three years after first dose of repotrectinib dose</time_frame>
    <description>To determine the confirmed ORR of repotrectinib (TPX-0005) as assessed by Blinded Independent Central Review (Phase 2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (CMAX) of repotrectinib (TPX-0005) (Phase 1)</measure>
    <time_frame>Up to 72 hours post dose</time_frame>
    <description>To determine the maximum plasma concentration (CMAX) of repotrectinib (TPX-0005)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) of repotrectinib (TPX-0005) (Phase 1)</measure>
    <time_frame>Up to 72 hours post dose</time_frame>
    <description>To determine the area under the plasma concentration time curve (AUC) of repotrectinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)</measure>
    <time_frame>Up to 72 hours post dose</time_frame>
    <description>To determine the area under the plasma concentration time curve (AUC) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (CMAX) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)</measure>
    <time_frame>Up to 72 hours post dose</time_frame>
    <description>To determine the maximum plasma concentration (CMAX) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) of midazolam(TPX-0005) (Phase 1)</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
    <description>To determine the area under the plasma concentration time curve (AUC) of midazolam(TPX-0005) (Phase 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (CMAX) of midazolam(TPX-0005) (Phase 1)</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
    <description>To determine the maximum plasma concentration (CMAX) of midazolam(TPX-0005) (Phase 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of repotrectinib following administration at RP2D (Phase 2)</measure>
    <time_frame>Pre dose and 4 hours post dose</time_frame>
    <description>To evaluate the plasma concentration of repotrectinib following administration at RP2D (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary objective response rate (ORR) (Phase 1)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the preliminary objective response rate (ORR) by Blinded Independent Central Review (BICR) (Phase 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) (Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the DOR of repotrectinib (TPX-0005) (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR) (Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the CBR of repotrectinib (TPX-0005) (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) (Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the PFS (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) (Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the OS (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial objective response rate (Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the intracranial objective response rate (Phase 2)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Locally Advanced Solid Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Repotrectinib (TPX-0005)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1&#xD;
Oral repotrectinib (TPX-0005):&#xD;
Phase 1a dose escalation, Phase 1b food-effect sub-study, and Phase 1c dose escalation with food, and Midazolam drug-drug interaction sub-study.&#xD;
Phase 2&#xD;
Oral repotrectinib (TPX-0005): 6 distinct expansion cohorts&#xD;
EXP-1: ROS1 TKI-naïve ROS1+ NSCLC&#xD;
EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC&#xD;
EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO)&#xD;
EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO)&#xD;
EXP-5: TRK TKI-naïve NTRK+ solid tumors&#xD;
EXP-6: TRK TKI-pretreated NTRK+ solid tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral repotrectinib (TPX-0005)</intervention_name>
    <description>Oral repotrectinib (TPX-0005) capsules.</description>
    <arm_group_label>Repotrectinib (TPX-0005)</arm_group_label>
    <other_name>repotrectinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PHASE 1&#xD;
&#xD;
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic&#xD;
             solid tumor (including primary CNS tumors) (Stage IV, American Joint Committee on&#xD;
             Cancer v.7) that harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by&#xD;
             protocol specified tests.&#xD;
&#xD;
          2. ECOG PS 0-1.&#xD;
&#xD;
          3. Age ≥18 (or age ≥ 20 of age as required by local regulation).&#xD;
&#xD;
          4. Capability to swallow capsules intact (without chewing, crushing, or opening).&#xD;
&#xD;
          5. At least 1 measurable target lesion according to RECIST version 1.1. CNS-only&#xD;
             measurable disease as defined by RECIST version 1.1 is allowed.&#xD;
&#xD;
          6. Prior cytotoxic chemotherapy is allowed.&#xD;
&#xD;
          7. Prior immunotherapy is allowed.&#xD;
&#xD;
          8. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer&#xD;
             therapy to National Cancer Institute Common Terminology Criteria for Adverse Events&#xD;
             (NCI CTCAE) Version 4.03 Grade less than or equal to 1.&#xD;
&#xD;
          9. Patients with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic&#xD;
             leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol&#xD;
             specified criteria.&#xD;
&#xD;
         10. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils&#xD;
             count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L);&#xD;
             Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine&#xD;
             clearance Within normal limits or &gt; 40 mL/min; Total serum bilirubin &lt; 1.5 × ULN;&#xD;
             Liver transaminases (ASTs/ALTs) &lt; 2.5 × ULN; &lt; 5 × ULN if liver metastases are present&#xD;
             Alkaline phosphatase (ALP); &lt; 2.5 × ULN; &lt; 5 × ULN if liver and/or bone metastasis are&#xD;
             present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or&#xD;
             without supplementation&#xD;
&#xD;
         11. Life expectancy ≥ 3 months.&#xD;
&#xD;
        PHASE 2 Key Inclusion Criteria&#xD;
&#xD;
          1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic&#xD;
             solid tumor (including primary CNS tumors) that harbors a ROS1, or NTRK1-3 gene&#xD;
             fusion.&#xD;
&#xD;
          2. Subject must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based&#xD;
             local testing using either:&#xD;
&#xD;
               1. a next-generation sequencing (NGS) or quantitative polymerase chain reaction&#xD;
                  (qPCR) test will be accepted to determine molecular eligibility.&#xD;
&#xD;
                  • Adequate tumor tissue needs to be sent to the Sponsor designated central&#xD;
                  diagnostic laboratory for retrospective confirmation by a central diagnostic&#xD;
                  laboratory test selected by the Sponsor.&#xD;
&#xD;
                  OR&#xD;
&#xD;
               2. a fluorescence in situ hybridization (FISH) test AND prospective confirmation of&#xD;
                  fusion status by a central diagnostic laboratory test selected by the Sponsor&#xD;
                  PRIOR to enrollment will be accepted to determine molecular eligibility.&#xD;
&#xD;
                    -  Adequate tumor tissue must be sent to the Sponsor designated central&#xD;
                       diagnostic laboratory for prospective confirmation by a central diagnostic&#xD;
                       laboratory test selected by the Sponsor PRIOR to enrollment.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.&#xD;
&#xD;
          4. Age ≥12 (or age ≥ 20 as required by local regulation).&#xD;
&#xD;
          5. Willing and able to provide written institutional review board (IRB)/institutional&#xD;
             ethics committee-approved Informed Consent or an Assent signed by a parent or legal&#xD;
             guardian for subjects age 12 to 17.&#xD;
&#xD;
          6. At least 1 measurable target lesion according to RECIST (v1.1) prospectively confirmed&#xD;
             by Blinded Independent Central Radiology Review (BICR), selected by Sponsor, PRIOR to&#xD;
             enrollment. Subjects with CNS-only measurable disease ≥10 mm as defined by RECIST&#xD;
             (v1.1) are eligible.&#xD;
&#xD;
          7. Subjects with advanced solid tumors harboring ROS1, NTRK1, NTRK2, or NTRK3&#xD;
             rearrangement will be assigned into 6 distinct expansion (EXP) cohorts provided all&#xD;
             inclusion and exclusion criteria are met.&#xD;
&#xD;
             i. EXP-1: ROS1 TKI-naïve ROS1+ NSCLC ii. EXP-2: 1 Prior ROS1 TKI and 1 Platinum based&#xD;
             chemo ROS1+ NSCLC iii. EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO) iv.&#xD;
             EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) v. EXP-5: TRK TKI-naïve NTRK+&#xD;
             solid tumors vi. EXP-6: TRK TKI-pretreated NTRK+ solid tumors&#xD;
&#xD;
          8. Subjects with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic&#xD;
             leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol&#xD;
             specified criteria.&#xD;
&#xD;
          9. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils&#xD;
             count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L);&#xD;
             Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine&#xD;
             clearance &gt; 40 mL/min; Total serum bilirubin &lt; 1.5 × ULN; Liver transaminases&#xD;
             (ASTs/ALTs) &lt; 2.5 × ULN; &lt; 5 × ULN if liver metastases are present Alkaline&#xD;
             phosphatase (ALP); &lt; 2.5 × ULN; &lt; 5 × ULN if liver and/or bone metastasis are present;&#xD;
             Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without&#xD;
             supplementation&#xD;
&#xD;
         10. Life expectancy ≥ 3 months.&#xD;
&#xD;
        Key Exclusion Criteria PHASE 1 and PHASE 2&#xD;
&#xD;
          1. Concurrent participation in another therapeutic clinical trial.&#xD;
&#xD;
          2. Symptomatic brain metastases or leptomeningeal involvement.&#xD;
&#xD;
          3. History of previous cancer, except for squamous cell or basal-cell carcinoma of the&#xD;
             skin, or any in situ carcinoma that has been completely resected, requiring therapy&#xD;
             within the previous 2 years.&#xD;
&#xD;
          4. Major surgery within 4 weeks of start of repotrectinib treatment. Radiation therapy&#xD;
             (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative&#xD;
             radiation (≤10 fractions) must have been completed at least 48 hours prior to study&#xD;
             entry&#xD;
&#xD;
          5. Clinically significant cardiovascular disease (either active or within 6 months prior&#xD;
             to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery&#xD;
             bypass graft, symptomatic congestive heart failure (New York Heart Association&#xD;
             Classification Class ≥ II), cerebrovascular accident or transient ischemic attack,&#xD;
             symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac&#xD;
             dysrhythmias of NCI CTCAE grade ≥2&#xD;
&#xD;
          6. Any of the following cardiac criteria:&#xD;
&#xD;
             Mean resting corrected QT interval (ECG interval measured from the onset of the QRS&#xD;
             complex to the end of the T wave) for heart rate (QTcF) &gt; 470 msec obtained from 3&#xD;
             ECGs, using the screening clinic ECG machine-derived QTc value Any clinically&#xD;
             important abnormalities in rhythm, conduction or morphology of resting ECG (e.g.,&#xD;
             complete left bundle branch block, third degree heart block, second degree heart&#xD;
             block, PR interval &gt; 250 msec) Any factors that increase the risk of QTc prolongation&#xD;
             or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT&#xD;
             syndrome, family history of long QT syndrome, or any concomitant medication known to&#xD;
             prolong the QT interval.&#xD;
&#xD;
          7. Known active infections (bacterial, fungal, viral including HIV positivity).&#xD;
&#xD;
          8. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut&#xD;
             syndrome) or other malabsorption syndromes that would impact drug absorption.&#xD;
&#xD;
          9. Peripheral neuropathy of CTCAE ≥grade 2.&#xD;
&#xD;
         10. History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4&#xD;
             interstitial fibrosis or interstitial lung disease including a history of pneumonitis,&#xD;
             hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease,&#xD;
             obliterative bronchiolitis, and pulmonary fibrosis. Subjects with history of prior&#xD;
             radiation pneumonitis are not excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shanna Stopatschinskaja, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Turning Point Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Liu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Zai Lab (Shanghai) Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shanna Stopatschinskaja, M.D.</last_name>
    <phone>(858) 276-0005</phone>
    <email>clinical@tptherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yuma Regional Medical Center PHASE 2</name>
      <address>
        <city>Yuma</city>
        <state>Arizona</state>
        <zip>85364</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>City of Hope PHASE 2</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marianna Koczywas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adventist Health Glendale PHASE 2</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mihran Shirinian, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MemorialCare Long Beach PHASE 2</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Oncology PHASE 2</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nishan Tchekmedyian, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health, Chao Family Comprehensive Cancer Center PHASE 1 (recruiting) &amp; PHASE 2 (recruiting)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Misako Nagasaka, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ventura County Hematology Oncology Specialists PHASE 2</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center PHASE 2</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lyudmila Bazhenova, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Joseph's Heritage Healthcare PHASE 2</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ian Anderson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver PHASE 1 (recruiting) &amp; PHASE 2 (recruiting)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ross Camidge, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center PHASE 2</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Kimmel Cancer Center PHASE 2</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benjamin Levy, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare System PHASE 2</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luis Raez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida PHASE 2</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Ocala Oncology PHASE 2</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center PHASE 2</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benjamin Creelan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Cancer and Blood Center PHASE 2</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Petros Nikolinakos, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute PHASE 2</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Pippas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hawaii Cancer Care PHASE 2</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago PHASE 2</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ardman Shergill, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care PHASE 2</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care PHASE 2</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Greg Gerstner, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology PHASE 2</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Beacon Health PHASE 2</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Pontchartrain Cancer Center (QCCA) PHASE 2</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine PHASE 2</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katherine Scilla, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer &amp; Blood Disorders - Maryland PHASE 2</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Frederick Health - James M Stockman Cancer Institute PHASE 2</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital PHASE 1 (recruiting) &amp; PHASE 2 (recruiting)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jessica Lin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MGH Satellite - Dana-Farber Cancer Institute PHASE 2</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Awad, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southcoast PHASE 2</name>
      <address>
        <city>Fairhaven</city>
        <state>Massachusetts</state>
        <zip>02719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Rogel Cancer Center PHASE 2</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute PHASE 2</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dipesh Uprety, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System PHASE 2</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shirish Gadgeel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sparrow Health System PHASE 2</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Regions Hospital Cancer Care Center PHASE 2</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arkadiusz Dudek, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Care Cancer Center PHASE 2</name>
      <address>
        <city>Bolivar</city>
        <state>Missouri</state>
        <zip>65613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Mosaic Life Care PHASE 2</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Washington University Siteman Cancer Center PHASE 2</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Haeseong Park, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Jersey Cancer Care and Blood Disorders PHASE 2</name>
      <address>
        <city>Belleville</city>
        <state>New Jersey</state>
        <zip>07109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group PHASE 2</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute PHASE 2</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Scott Moerdler, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health PHASE 2</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vamsidhar Velcheti, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center PHASE 1 (recruiting) &amp; PHASE 2 (Recruiting)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander Drilon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern PHASE 2</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center PHASE 2</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nashat Gabrail, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TriHealth Cancer Institute PHASE 2</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Faisal Adhami, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic PHASE 2</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Anderson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State Wexner Medical Center PHASE 2</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dwight Owen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OhioHealth PHASE 2</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>University of Toledo PHASE 2</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists and Research Institute Tulsa, OK (OCSRI) (QCCA) PHASE 2</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Gettysburg PHASE 2</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center PHASE 2</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jessica Bauman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Health PHASE 2</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute Center for Precision Oncology PHASE 2</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center PHASE 2</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Muhammad Beg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center - The University of Texas PHASE 2</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yasir Elamin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants P.A. PHASE 2</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists PHASE 2</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists PHASE 2</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alex Spria, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Fredericksburg PHASE 2</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>PeaceHealth - Bellingham (NW) PHASE 2</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>UW Seattle Cancer Care Alliance PHASE 2</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christina Baik, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ThedaCare PHASE 2</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>The Chris O-Brien Lifehouse PHASE 2</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steven Kao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre PHASE 2</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christos Karapetis, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Center PHASE 2</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3501</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ben Solomon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZA Research Unit Oncology- route 55 PHASE 2</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans Prenen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Campus Gasthuisberg PHASE 2</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe Dooms, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute PHASE 2</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Quincy Chu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Osler Health System PHASE 2</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 37R</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Parneet Cheema, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital PHASE 2</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Wheatley-Price, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center at University Health Network PHASE 2</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Geoffrey Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital/Oncology Department PHASE 2</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yueyin Pan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences/Cancer Institute PHASE 2</name>
      <address>
        <city>Chaoyang</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Junling Li, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital/Oncology Department PHASE 2</name>
      <address>
        <city>Haidian</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jian Fang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital Sichuan University/Lung cancer center PHASE 2</name>
      <address>
        <city>Wenjiang</city>
        <state>Chengdu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Feng Luo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daping Hospital, the Third Affiliated Hospital of Third Military Medical University /Cancer Center PHASE 2</name>
      <address>
        <city>Daping</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yong He, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first Hospital Affiliated to AMU (Southwest Hospital)/Pneumology Department PHASE 2</name>
      <address>
        <city>Shapingba</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Liang Gong, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University/Medical oncology Department PHASE 2</name>
      <address>
        <city>Fujian</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jingxun Wu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital/Thoracic oncology Department PHASE 2</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gen Lin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital PHASE 2</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jinji Yang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Tumor Hospital of Harbin Medical University/Medical Oncology Department PHASE 2</name>
      <address>
        <city>Heilongjiang</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yang Yu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital/The 1st pneumology department PHASE 2</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xiufeng Hu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology/Cancer Center Department PHASE 2</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xiaorong Dong, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second XIANGYA Hospital Of Central South University/Oncology Department PHASE 2</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chunhong Hu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University/Department of Respiratory and Critical Care Medicine PHASE 2</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jie Meng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital PHASE 2</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Liyun Miao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>XuZhou Central Hospital/Oncology Department PHASE 2</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xiang Wu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital/Medical Oncology Department PHASE 2</name>
      <address>
        <city>Jilin</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ying Cheng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University/Oncology Center Department PHASE 2</name>
      <address>
        <city>Jilin</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jiuwei Cui, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer hospital PHASE 2</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rui Ma, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital/Medical Oncology Department PHASE 2</name>
      <address>
        <city>Shandong</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Meili Sun, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weifang People's Hospital/Medical Oncology Department PHASE 2</name>
      <address>
        <city>Shandong</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guohua Yu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital/Chest Cancer Institute PHASE 2</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Liyan Jiang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital/Oncology Department PHASE 2</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shun Lu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Bethune Hospital PHASE 2</name>
      <address>
        <city>Shanxi</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Junping Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital PHASE 2</name>
      <address>
        <city>Shanxi</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Haichuan Su, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital/Medical Oncology Department PHASE 2</name>
      <address>
        <city>Sichuan</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wenxiu Yao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital/Medical Oncology Department PHASE 2</name>
      <address>
        <city>Yuelu</city>
        <state>Yuelu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nong Yang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Gannan Medical University PHASE 2</name>
      <address>
        <city>Zhanggong</city>
        <state>Zhanggong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Huaqiu Shi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital Zhejiang University School of Medicine/Oncology Department PHASE 2</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kejing Ying, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital/Thoracic Oncology Department PHASE 2</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yping Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Zhejiang University School of Medicine/Respiratory medicine Department PHASE 2</name>
      <address>
        <city>Zhejiang</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jianying Zhou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, University Hospital of Copenhagen PHASE 2</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kristoffer Rohrberg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Vuniversitaire Brest PHASE 2</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles Robinet, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges-Francois PHASE 2</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alice Hervieu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitarie Arie Grenoble Alpes (CHUGA) PHASE 2</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Denis Moro-Sibilot, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Timone PHASE 2</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurent Greillier, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers PHASE 2</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas Isambert, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital D'Instruction Des Armees Begin PHASE 2</name>
      <address>
        <city>Saint-Mandé</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carole Helissey, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy PHASE 2</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benjamin Besse, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evangelische Lungenklinik Berlin PHASE 2</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Grohe, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum für Integrierte Onkologie - Universitaetsklinikum Koeln PHASE 2</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jurgen Wolf, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinic Carl Gustav Carus PHASE 2</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Wermke, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg PHASE 2</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Springfield, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital PHASE 2</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Ho, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital PHASE 2</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Yau, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hong Kong United Oncology Centre PHASE 2</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacky Li, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital PHASE 2</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Herbert Loong, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem PHASE 2</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Veronika Muller, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Di Riferimento PHASE 2</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alessandra Bearz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS CA Granda Ospedale Maggiore Policlinico PHASE 2</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudia Maria Bareggi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale Dei Tumori PHASE 2</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marina Garassino, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti &quot;Villa Sofia - Cerevello&quot; PHASE 2</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Verderame, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova PHASE 2</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Pagano, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Regina Elena Oncologia Medica 1 PHASE 2</name>
      <address>
        <city>Roma</city>
        <zip>144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Federico Cappuzzo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria di Terni - PHASE 2</name>
      <address>
        <city>Terni</city>
        <zip>5100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sergio Bracarda, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital PHASE 2</name>
      <address>
        <city>Cheongju-si</city>
        <state>Chungcheongbuk-do</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ki Hyeong Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital PHASE 2</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Young-Chul Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital PHASE 2</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dong-Wan Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center PHASE 2</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kye-Young Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center PHASE 2</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sang-We Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center PHASE 2</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeeyun Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul Saint Mary's Hospital PHASE 2</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jin-Hyoung Kang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital PHASE 1 (recruiting) and PHASE 2 (not yet recruiting)</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dong-Wan Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei Cancer Center, Severance Hospital PHASE 1 (recruiting) &amp; PHASE 2 (recruiting)</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Byoung Chul Cho, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center PHASE 1</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeeyun Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute PHASE 2</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joop de Langen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universiair Medisch Centrum Groningen PHASE 2</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anthonie Van der Wekken, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne Klinika Onkologii i Radioterapii PHASE 2</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rafal Dziadziuszko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Pneumonologii, Onkologii i Alergologii Uniwersytetu Medycznego w Lublinie PHASE 2</name>
      <address>
        <city>Lublin</city>
        <zip>20-609</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pawel Krawczyk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Med Polonia, ul. Obornicka PHASE 2</name>
      <address>
        <city>Poznan</city>
        <zip>60693</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rodryg Ramlau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Dom Lekarski PHASE 2</name>
      <address>
        <city>Szczecin</city>
        <zip>70784</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Piotr Serwatowski, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Cancer Centre and Institute PHASE 2</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dariusz Kowalski, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Hospital PHASE 2</name>
      <address>
        <city>Singapore</city>
        <state>Central Singapore</state>
        <zip>119704</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ross Soo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Singapore PHASE 2</name>
      <address>
        <city>Singapore</city>
        <state>Central Singapore</state>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Darren Lim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra PHASE 2</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ignacio Gil-Bazo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dexeus - Grupo Quironsalud PHASE 2</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andres Aguilar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital PHASE 2</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enriqueta Felip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion MD Anderson PHASE 2</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enrique Grande, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START Madrid-FJD PHASE 2</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Victor Moreno, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre PHASE 2</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luis Paz-Ares, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital HM Sanchinarro PHASE 2</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emiliano Calvo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología PHASE 2</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angel Guerrero, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital PHASE 2</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chia-Jui Yen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital PHASE 2</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Yang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital PHASE 2</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tsang-En Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust PHASE 2</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sanjay Popat, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College London - Hammersmith Hospital PHASE 2</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Pinato, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute PHASE 2</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anna Patrikidou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust PHASE 2</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew Krebs, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALK</keyword>
  <keyword>ROS1</keyword>
  <keyword>NTRK</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Carcinoma, NSCL</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Non Small Cell Lung</keyword>
  <keyword>Thyroid Disease</keyword>
  <keyword>Colonic Neoplasms</keyword>
  <keyword>Thyroid Neoplasms</keyword>
  <keyword>Carcinoma, Neuroendocrine</keyword>
  <keyword>Respiratory Tract Neoplasms</keyword>
  <keyword>Thoracic Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Lung Disease</keyword>
  <keyword>Respiratory Tract Disease</keyword>
  <keyword>Carcinoma, Bronchogenic</keyword>
  <keyword>Bronchial Neoplasms</keyword>
  <keyword>Endocrine System Disease</keyword>
  <keyword>Colorectol Neoplasms</keyword>
  <keyword>Intestinal Neoplasms</keyword>
  <keyword>Gastrointestinal Neoplasms</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Gastrointestinal Disease</keyword>
  <keyword>Colonic Disease</keyword>
  <keyword>Intestinal Disease</keyword>
  <keyword>Endocrine Gland Neoplasms</keyword>
  <keyword>Head and Neck Neoplasms</keyword>
  <keyword>Neuroendocrine Tumors</keyword>
  <keyword>Neuroectodermal Tumors</keyword>
  <keyword>Neoplasms, Germ Cell and Embryonal</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Rearrangements</keyword>
  <keyword>TRIDENT-1</keyword>
  <keyword>TKI</keyword>
  <keyword>TKI naive</keyword>
  <keyword>TKI pretreated</keyword>
  <keyword>Anti-tumor activity</keyword>
  <keyword>Repotrectinib</keyword>
  <keyword>Advanced Solid Malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There are no plans to share individual participant data with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

